Vital Therapies, Inc. (Nasdaq: VTL) 79.6% LOWER; announced that topline results from VTI-208, the Company's phase 3 randomized, controlled, open-label ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE